Lumos Diagnostics Partners with PRO-spectus to Accelerate Market Access for FebriDx
14 August 2025
Lumos Diagnostics has today announced that it has entered into a partnering agreement with US-based market access consultancy, PRO-spectus, to support the marketing, market access and reimbursement of its flagship point-of-care test, FebriDx®.
PRO-spectus is a leading independent provider of patient access programs and specialty pharmacy services for the life sciences industry.
Under the agreement, PRO-spectus will provide a comprehensive suite of strategic and operational services designed to help accelerate patient access to FebriDx® by supporting healthcare providers in securing appropriate reimbursement.
These will include:
Development of strategic collateral to communicate FebriDx’s® clinical and economic value across multiple healthcare settings.
Lumos CEO, Doug Ward, said:
“This partnership with PRO-spectus is an important step in accelerating the commercial adoption of FebriDx® in the US market. By combining our clinically proven diagnostic technology with PRO-spectus’ market access expertise, we can better equip healthcare providers to secure reimbursement and accelerate the adoption of FebriDx®. Ultimately, this means reducing unnecessary antibiotic use, improving patient outcomes, and helping to address the growing challenge of antimicrobial resistance.”
The program will initially run through to December 2026.
Click to read the ASX release.
PRO-spectus is a leading independent provider of patient access programs and specialty pharmacy services for the life sciences industry.
Under the agreement, PRO-spectus will provide a comprehensive suite of strategic and operational services designed to help accelerate patient access to FebriDx® by supporting healthcare providers in securing appropriate reimbursement.
These will include:
Development of strategic collateral to communicate FebriDx’s® clinical and economic value across multiple healthcare settings.
- A dedicated helpline to respond to coding, coverage, and payment inquiries from both internal stakeholders and external customers.
- A field support team with expertise in provider adoption of new technologies, working directly with strategic accounts to deliver reimbursement education, navigate payor requirements, and resolve site-specific billing and coding challenges.
Lumos CEO, Doug Ward, said:
“This partnership with PRO-spectus is an important step in accelerating the commercial adoption of FebriDx® in the US market. By combining our clinically proven diagnostic technology with PRO-spectus’ market access expertise, we can better equip healthcare providers to secure reimbursement and accelerate the adoption of FebriDx®. Ultimately, this means reducing unnecessary antibiotic use, improving patient outcomes, and helping to address the growing challenge of antimicrobial resistance.”
The program will initially run through to December 2026.
Click to read the ASX release.
